PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
These metrics indicate whether the stock trades cheaply or expensively relative to its fundamentals. Value investors use them to find mispricings—buying stocks that appear undervalued, with solid long-term prospects and limited downside risk.
-0.96
Negative P/E while Biotechnology median is -4.58. Seth Klarman would scrutinize path to profitability versus peers.
No Data
No Data available this quarter, please select a different quarter.
28.01
P/B exceeding 1.5x Biotechnology median of 2.24. Jim Chanos would check for potential asset write-down risks.
-6.17
Negative FCF while Biotechnology median P/FCF is -17.51. Seth Klarman would investigate cash flow improvement potential.
-6.17
Negative operating cash flow while Biotechnology median P/OCF is -17.49. Seth Klarman would investigate operational improvement potential.
28.01
Fair value ratio exceeding 1.5x Biotechnology median of 2.18. Jim Chanos would check for valuation bubble risks.
-26.00%
Negative earnings while Biotechnology median yield is -2.46%. Seth Klarman would investigate path to profitability.
-16.21%
Negative FCF while Biotechnology median yield is -1.83%. Seth Klarman would investigate cash flow improvement potential.